[00:28:40] Emily Field: Because if we just want this whole episode talking about why muscle matters, why training matters, and why preserving strength matters, then we also have to acknowledge this
Importantly, this decision applied only to the obesity indication ( 7 , 8 )
Once-Weekly Semaglutide in Adults With Overweight or Obesity (STEP-1 Trial, 2021) showed significant weight loss and metabolic improvements with weekly semaglutide + lifestyle intervention versus placebo
Because this is a benefit exclusion not a medical-necessity denial prior-authorization paperwork will not change the outcome
What is multidistrict litigation (MDL), and does it apply to these cases
If pharmacy transparency matters to you, look elsewhere